Paraoxonase activity and coronary heart disease risk in healthy middle-aged males: The PRIME study

Atherosclerosis

Volumn 197, Issue 2, 2008, Pages 556-563

  Troughton, J A ^a   Woodside, J V ^a   Yarnell, J W G ^a   Arveiler, D ^b   Amouyel, P ^c   Ferrieres J ^d   Ducimetiere P ^e   Patterson, C C ^a   Luc, G ^c  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b UNIVERSITÉ DE STRASBOURG   (France)

^c INSTITUT PASTEUR DE LILLE   (France)

^d INSERM   (France)

^e HÔPITAL PAUL BROUSSE   (France)

Author keywords

Cohort; Coronary heart disease; Paraoxonase; PON55; PRIME; Prospective

Indexed keywords

ARYLDIALKYLPHOSPHATASE;

ADULT; ARTICLE; CASE CONTROL STUDY; CORONARY RISK; ENZYME ACTIVITY; FOLLOW UP; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

APOLIPOPROTEIN A-I; ARYLDIALKYLPHOSPHATASE; CASE-CONTROL STUDIES; CORONARY DISEASE; FOLLOW-UP STUDIES; FRANCE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; NORTHERN IRELAND; NUTRITION SURVEYS; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS;

EID: 40949098979     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2007.08.019     Document Type: Article

References (41)

1. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362 (1993) 801-809
2. Heller R.F., Chinn S., Pedoe H.D., and Rose G. How well can we predict coronary heart disease? Findings in the United Kingdom Heart Disease Prevention Project. Br Med J (Clin Res Ed) 288 (1984) 1409-1411
3. Yarnell J.W. The PRIME study: classical risk factors do not explain the several fold differences in risk of coronary heart disease between France and Northern Ireland. Prospective Epidemiological Study of Myocardial Infarction. QJM 91 (1998) 667-676
4. Scarabin P.Y., Arveiler D., Amouyel P., et al. Plasma fibrinogen explains much of the difference in risk of coronary heart disease between France and Northern Ireland. The PRIME study. Atherosclerosis 166 (2003) 103-109
5. Blatter M.C., James R.W., Messmer S., Barja F., and Pometta D. Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45. Identity of K-45 with paraoxonase. Eur J Biochem 211 (1993) 871-879
6. Adkins S., Gan K.N., Mody M., and La Du B.N. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet 52 (1993) 598-608
7. Humbert R., Adler D.A., Disteche C.M., et al. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet 3 (1993) 73-76
8. Mackness B., Mackness M.I., Arrol S., Turkie W., and Durrington P.N. Effect of the molecular polymorphisms of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon. Br J Pharmacol 122 (1997) 265-268
9. Mackness M.I., Arrol S., Abbott C., and Durrington P.N. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 104 (1993) 129-135
10. Aviram M., Rosenblat M., Bisgaier C.L., et al. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest 101 (1998) 1581-1590
11. Aviram M., Rosenblat M., Billecke S., et al. Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic Biol Med 26 (1999) 892-904
12. Mackness B., Mackness M.I., Arrol S., Turkie W., and Durrington P.N. Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Lett 423 (1998) 57-60
13. Mackness B., Durrington P., McElduff P., et al. Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation 107 (2003) 2775-2779
14. Mackness B., Mackness M.I., Durrington P.N., et al. Paraoxonase activity in two healthy populations with differing rates of coronary heart disease. Eur J Clin Invest 30 (2000) 4-10
15. Tunstall-Pedoe H., Kuulasmaa K., Amouyel P., et al. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in 4 continents. Circulation 90 (1994) 583-612
16. Ducimetiere P., Ruidavets J.B., Montaye M., Haas B., and Yarnell J. Five-year incidence of angina pectoris and other forms of coronary heart disease in healthy men aged 50-59 in France and Northern Ireland: the Prospective Epidemiological Study of Myocardial Infarction (PRIME) Study. Int J Epidemiol 30 (2001) 1057-1062
17. Rose G.A., Blackburn H., Gillum R.R., and Prineas R.J. Cardiovascular survey methods. 2nd ed. (1982), World Health Organisation, Geneva
18. Ortigoza-Ferado J., Richter R.J., Hornung S.K., Motulsky A.G., and Furlong C.E. Paraoxon hydrolysis in human serum mediated by a genetically variable arylesterase and albumin. Am J Hum Genet 36 (1984) 295-305
19. Gan K.N., Smolen A., Eckerson H.W., and Ladu B.N. Purification of human serum paraoxonase arylesterase-evidence for one esterase catalyzing both activities. Drug Metab Dispos 19 (1991) 100-106
20. Luc G., Bard J.M., Ferrieres J., et al. Value of HDL cholesterol, apolipoprotein A-I, lipoprotein A-I, and lipoprotein A-I/A-II in prediction of coronary heart disease: the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction. Arterioscler Thromb Vasc Biol 22 (2002) 1155-1161
21. Mackness B., Durrington P., and Mackness M. Human serum paraoxonase. Gen Pharmacol 31 3 (1998) 329-336
22. Ayub A., Mackness M.I., Arrol S., et al. Serum paraoxonase after myocardial infarction. Arterioscler Thromb Vasc Biol 19 (1999) 330-335
23. Mackness B., Davies G.K., Turkie W., et al. Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype?. Arterioscler Thromb Vasc Biol 21 (2001) 1451-1457
24. Wilson P.W., D'Agostino R.B., Levy D., et al. Prediction of coronary heart disease using risk factor categories. Circulation 97 (1998) 1837-1847
25. Ruiz J., Blanche H., James R.W., et al. Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet 346 (1995) 869-872
26. Jarvik G.P., Rozek L.S., Brophy V.H., et al. Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1(192) or PON1(55) genotype. Arterioscler Thromb Vasc Biol 20 (2000) 2441-2447
27. Horter M.J., Sondermann S., Reinecke H., et al. Associations of HDL phospholipids and paraoxonase activity with coronary heart disease in postmenopausal women. Acta Physiol Scand 176 (2002) 123-130
28. Karakaya A., Ibis S., Kural T., Kose S.K., and Karakaya A.E. Serum paraoxonase activity and phenotype distribution in Turkish subjects with coronary heart disease and its relationship to serum lipids and lipoproteins. Chem Biol Interact 118 (1999) 193-200
29. Rahmani M., Raiszadeh F., Allahverdian S., et al. Coronary artery disease is associated with the ratio of apolipoprotein A-I/B and serum concentration of apolipoprotein B, but not with paraoxonase enzyme activity in Iranian subjects. Atherosclerosis 162 (2002) 381-389
30. Jarvik G.P., Hatsukami T.S., Carlson C., et al. Paraoxonase activity, but not haplotype utilizing the linkage disequilibrium structure, predicts vascular disease. Arterioscler Thromb Vasc Biol 23 (2003) 1465-1471
31. Brophy V.H., Hastings M.D., Clendenning J.B., et al. Polymorphisms in the human paraoxonase (PON1) promoter. Pharmacogenetics 11 (2001) 77-84
32. Brophy V.H., Jampsa R.L., Clendenning J.B., et al. Effects of 5′ regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. Am J Hum Genet 68 (2001) 1428-1436
33. Leviev I., and James R.W. Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler Thromb Vasc Biol 20 (2000) 516-521
34. Suehiro T., Nakamura T., Inoue M., et al. A polymorphism upstream from the human paraoxonase (PON1) gene and its association with PON1 expression. Atherosclerosis 150 (2000) 295-298
35. Wang X., Fan Z., Huang J., et al. Extensive association analysis between polymorphisms of PON gene cluster with coronary heart disease in Chinese Han population. Arterioscler Thromb Vasc Biol 23 (2003) 328-334
36. James R.W., Leviev I., Ruiz J., et al. Promoter polymorphism T(-107)C of the paraoxonase PON1 gene is a risk factor for coronary heart disease in type 2 diabetic patients. Diabetes 49 (2000) 1390-1393
37. Schmidt H., Schmidt R., Niederkorn K., et al. Paraoxonase PON1 polymorphism leu-Met54 is associated with carotid atherosclerosis: results of the Austrian Stroke Prevention Study. Stroke 29 (1998) 2043-2048
38. Malin R., Jarvinen O., Sisto T., Koivula T., and Lehtimaki T. Paraoxonase producing PON1 gene M/L55 polymorphism is related to autopsy-verified artery-wall atherosclerosis. Atherosclerosis 157 (2001) 301-307
39. Fortunato G., Rubba P., Panico S., et al. A paraoxonase gene polymorphism, PON 1 (55), as an independent risk factor for increased carotid intima-media thickness in middle-aged women. Atherosclerosis 167 (2003) 141-148
40. Wheeler J.G., Keavney B.D., Watkins H., Collins R., and Danesh J. Four paraoxonase gene polymorphisms in 11,212 cases of coronary heart disease and 12,786 controls: meta-analysis of 43 studies. Lancet 363 (2004) 689-695
41. Sanghera D.K., Saha N., and Kamboh M.I. The codon 55 polymorphism in the paraoxonase 1 gene is not associated with the risk of coronary heart disease in Asian Indians and Chinese. Atherosclerosis 136 (1998) 217-223